Establishment and assessment of a new human embryonic stem cell-based biomarker assay for developmental toxicity screening.

A metabolic biomarker-based in vitro assay utilizing human embryonic stem (hES) cells was developed to identify the concentration of test compounds that perturbs cellular metabolism in a manner indicative of teratogenicity. This assay is designed to aid the early discovery-phase detection of potential human developmental toxicants. In this study, metabolomic data from hES cell culture media were used to assess potential biomarkers for development of a rapid in vitro teratogenicity assay. hES cells were treated with pharmaceuticals of known human teratogenicity at a concentration equivalent to their published human peak therapeutic plasma concentration. Two metabolite biomarkers (ornithine and cystine) were identified as indicators of developmental toxicity. A targeted exposure-based biomarker assay using these metabolites, along with a cytotoxicity endpoint, was then developed using a 9-point dose-response curve. The predictivity of the new assay was evaluated using a separate set of test compounds. To illustrate how the assay could be applied to compounds of unknown potential for developmental toxicity, an additional 10 compounds were evaluated that do not have data on human exposure during pregnancy, but have shown positive results in animal developmental toxicity studies. The new assay identified the potential developmental toxicants in the test set with 77% accuracy (57% sensitivity, 100% specificity). The assay had a high concordance (≥75%) with existing in vivo models, demonstrating that the new assay can predict the developmental toxicity potential of new compounds as part of discovery phase testing and provide a signal as to the likely outcome of required in vivo tests.

[1]  David J. Greenblatt,et al.  Doxylamine and Diphenhydramine Pharmacokinetics in Women on Low‐Dose Estrogen Oral Contraceptives , 1989, Journal of clinical pharmacology.

[2]  A. Piersma,et al.  A different approach to validating screening assays for developmental toxicity. , 2010, Birth defects research. Part B, Developmental and reproductive toxicology.

[3]  L. Wise,et al.  The role of maternal toxicity in lovastatin-induced developmental toxicity. , 2004, Birth defects research. Part B, Developmental and reproductive toxicology.

[4]  Biagio Mazzi,et al.  About the Web Site , 2013 .

[5]  Clive N. Svendsen,et al.  Human stem cells and drug screening: opportunities and challenges , 2010, Nature Reviews Drug Discovery.

[6]  Julieta M. Panzica-Kelly,et al.  Development of a zebrafish embryo teratogenicity assay and quantitative prediction model. , 2010, Birth defects research. Part B, Developmental and reproductive toxicology.

[7]  J Stadler,et al.  Interlaboratory evaluation of embryotoxicity in the postimplantation rat embryo culture. , 1995, Reproductive toxicology.

[8]  K. Herrmann,et al.  Teratogenic effects of retinoic acid and related substances on the early development of the zebrafish (Brachydanio rerio) as assessed by a novel scoring system. , 1995, Toxicology in vitro : an international journal published in association with BIBRA.

[9]  P. West,et al.  Predicting human developmental toxicity of pharmaceuticals using human embryonic stem cells and metabolomics. , 2010, Toxicology and applied pharmacology.

[10]  I. Rietjens,et al.  Relative developmental toxicity potencies of retinoids in the embryonic stem cell test compared with their relative potencies in in vivo and two other in vitro assays for developmental toxicity. , 2011, Toxicology letters.

[11]  I. Mahmood,et al.  A limited sampling method for the estimation of AUC and Cmax of carbamazepine and carbamazepine epoxide following a single and multiple dose of a sustained-release product. , 1998, British journal of clinical pharmacology.

[12]  Aldert Piersma,et al.  A Review of the Implementation of the Embryonic Stem Cell Test (EST) , 2009, Alternatives to laboratory animals : ATLA.

[13]  Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling. Final rule. , 2014, Federal register.

[14]  E. Lammer.  Teratology Society Position Paper: Recommendations for Vitamin A Use During Pregnancy , 1987, Teratology.

[15]  N. Brown.  Selection of Test Chemicals for the ECVAM International Validation Study on In Vitro Embryotoxicity Tests , 2002, Alternatives to laboratory animals : ATLA.

[16]  L. Vlase,et al.  Pharmacokinetic interaction study between ranitidine and metoclopramide. , 2004, Romanian journal of gastroenterology.

[17]  S. Sallan,et al.  Pharmacokinetics of continuous intravenous and subcutaneous infusions of cytosine arabinoside. , 1982, Blood.

[18]  Robert E Chapin,et al.  Assessment of the Embryonic Stem Cell Test and application and use in the pharmaceutical industry. , 2008, Birth defects research. Part B, Developmental and reproductive toxicology.

[19]  Qigui Li,et al.  Pharmacokinetic profiles of artesunate following multiple intravenous doses of 2, 4, and 8 mg/kg in healthy volunteers: Phase 1b study , 2012, Malaria Journal.

[20]  A. Shad,et al.  NTP-CERHR expert panel report on the reproductive and developmental toxicity of hydroxyurea. , 2007, Birth defects research. Part B, Developmental and reproductive toxicology.

[21]  Julieta M. Panzica-Kelly,et al.  Inter-laboratory assessment of a harmonized zebrafish developmental toxicology assay - progress report on phase I. , 2012, Reproductive toxicology.

[22]  R. Clark.  Embryotoxicity of the artemisinin antimalarials and potential consequences for use in women in the first trimester. , 2009, Reproductive toxicology.

[23]  A. Pegg.  Mammalian polyamine metabolism and function , 2009, IUBMB life.

[24]  Stephen M Hewitt,et al.  Vitamin C Pharmacokinetics: Implications for Oral and Intravenous Use , 2004, Annals of Internal Medicine.

[25]  Germán Novoa-Heckel,et al.  Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects. , 2007, Clinical therapeutics.

[26]  S. Kalhan,et al.  Protein and amino acid metabolism in the human newborn. , 2008, Annual review of nutrition.

[27]  T. Knudsen,et al.  Fundamental Concepts, Current Regulatory Design and Interpretation , 2010 .

[28]  D. Tolbert,et al.  Disposition Kinetics and Tolerance of Escalating Single Doses of Ramelteon, a High‐Affinity MT1 and MT2 Melatonin Receptor Agonist Indicated for Treatment of Insomnia , 2006, Journal of clinical pharmacology.

[29]  T. Shepard.  Catalog of Teratogenic Agents , 1973 .

[30]  R. Larson,et al.  Phase II Trial of Oral Aminopterin for Adults and Children with Refractory Acute Leukemia , 2005, Clinical Cancer Research.

[31]  Kjell Johnson,et al.  Not a walk in the park: the ECVAM whole embryo culture model challenged with pharmaceuticals and attempted improvements with random forest design. , 2011, Birth defects research. Part B, Developmental and reproductive toxicology.

[32]  P. Brown-Woodman,et al.  Effect of co-administration of retinoids on rat embryo development in vitro. , 2003, Birth defects research. Part A, Clinical and molecular teratology.

[33]  T. Lau,et al.  Effect of rosiglitazone on embryonic growth and morphology: a study using a whole rat embryo culture model. , 2006, Fertility and sterility.

[34]  D. Mattison,et al.  Prediction of risk for human developmental toxicity: How important are animal studies for hazard identification? , 1989, Obstetrics and gynecology.

[35]  G. Varela-Moreiras,et al.  Physiologic changes in homocysteine metabolism in pregnancy: a longitudinal study in Spain. , 2011, Nutrition.

[36]  G. Greenberg,et al.  Drugs in Pregnancy and Lactation , 1990 .

[37]  H. Nau,et al.  Influence of 13-cis and all- trans retinoic acid on rat embryonic development in vitro: correlation with isomerisation and drug transfer to the embryo , 2004, Archives of Toxicology.

[38]  A. Piersma,et al.  Innovative approaches in the embryonic stem cell test (EST). , 2012, Frontiers in bioscience.

[39]  R. Warrell,et al.  Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. , 1992, Cancer research.

[40]  H. Merker,et al.  Effect of acyclovir on mammalian embryonic development in culture , 1985, Archives of Toxicology.

[41]  A. Treiber,et al.  Inhibitory and Inductive Effects of Rifampin on the Pharmacokinetics of Bosentan in Healthy Subjects , 2007, Clinical pharmacology and therapeutics.

[42]  Melvin E. Andersen,et al.  Toxicity Testing in the 21st Century: Defining New Risk Assessment Approaches Based on Perturbation of Intracellular Toxicity Pathways , 2011, PloS one.

[43]  C. Cruzeiro,et al.  The toxicity potential of pharmaceuticals found in the Douro River estuary (Portugal)--experimental assessment using a zebrafish embryo test. , 2011, Environmental toxicology and pharmacology.

[44]  Joshua F. Robinson,et al.  Embryotoxicant-specific transcriptomic responses in rat postimplantation whole-embryo culture. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[45]  Clay W Scott,et al.  Human induced pluripotent stem cells and their use in drug discovery for toxicity testing. , 2013, Toxicology letters.

[46]  E. Radwanski,et al.  Pharmacokinetics and Dose Proportionality of Loratadine , 1987, Journal of clinical pharmacology.

[47]  B. Gustavsson,et al.  Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous Vasopressin in non-resectable pancreas cancer , 2005, Cancer Chemotherapy and Pharmacology.

[48]  R. Blomhoff,et al.  Exposure to Retinyl Esters, Retinol, and Retinoic Acids in Non-Pregnant Women following Increasing Single and Repeated Oral Doses of Vitamin A , 2005, Annals of Nutrition and Metabolism.

[49]  Bernard Guyer,et al.  Annual Summary of Vital Statistics: 2004 , 2006, Pediatrics.

[50]  Thomas Braunbeck,et al.  Zebrafish (Danio rerio) embryos as a model for testing proteratogens. , 2011, Toxicology.

[51]  D J Dix,et al.  Identifying developmental toxicity pathways for a subset of ToxCast chemicals using human embryonic stem cells and metabolomics. , 2011, Toxicology and applied pharmacology.

[52]  Jens C. Streibig,et al.  Bioassay analysis using R , 2005 .

[53]  P. Kovacic,et al.  Mechanism of teratogenesis: electron transfer, reactive oxygen species, and antioxidants. , 2006, Birth defects research. Part C, Embryo today : reviews.

[54]  R. Abagyan,et al.  XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. , 2006, Analytical chemistry.

[55]  Patricia McGrath,et al.  Zebrafish: a predictive model for assessing drug-induced toxicity. , 2008, Drug discovery today.

[56]  Higher maximal serum concentration of methotrexate predicts the incidence of adverse reactions in Japanese rheumatoid arthritis patients , 2007, Modern rheumatology.

[57]  N. Volpato,et al.  Comparative Bioavailability of Two Oral L-Thyroxine Formulations after Multiple Dose Administration in Patients with Hypothyroidism and its Relation with Therapeutic Endpoints and Dissolution Profiles , 2001, Arzneimittelforschung.

[58]  J. Hansen.  Oxidative stress as a mechanism of teratogenesis. , 2006, Birth defects research. Part C, Embryo today : reviews.

[59]  Susanne Bremer,et al.  Validation of the Embryonic Stem Cell Test in the International ECVAM Validation Study on Three In Vitro Embryotoxicity Tests , 2004, Alternatives to laboratory animals : ATLA.

[60]  Julieta M. Panzica-Kelly,et al.  Development of a streamlined rat whole embryo culture assay for classifying teratogenic potential of pharmaceutical compounds. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[61]  R. Blust,et al.  Feasibility study of the zebrafish assay as an alternative method to screen for developmental toxicity and embryotoxicity using a training set of 27 compounds. , 2012, Reproductive toxicology.

[62]  C. Beglinger,et al.  Effect of intravenous infusions of thiamine on the disposition kinetics of thiamine and its pyrophosphate , 2003, Journal of clinical pharmacy and therapeutics.